-+ 0.00%
-+ 0.00%
-+ 0.00%

Kazia Therapeutics And The Hebrew University Of Jerusalem Receives A Grant From The Michael J. Fox Foundation To Evaluate The Therapeutic Potential Of Paxalisib As A Treatment For Parkinson's Disease; No Financial Terms Disclosed

Benzinga·02/20/2025 13:48:13
Listen to the news

Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced a research grant awarded from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to fund research between The Hebrew University of Jerusalem (Hebrew University) and Kazia to explore the therapeutic potential of paxalisib as a treatment for Parkinson's disease (PD).

The grant will fund collaborative preclinical studies at Professor Ronit Sharonʼs lab (Hebrew University) aimed at establishing an operational link between a specific pathway in the pathophysiology of PD and paxalisib. The research will assess the impact of paxalisib on mouse survival, motor and non-motor performances, as well as specific biochemical, pathological and molecular disease biomarkers that will be determined in brains of treated mice. Paxalisib is a unique, blood-brain barrier-penetrating inhibitor for class IA phosphatidylinositol 3-kinase (PI3K), and data generated from this research is expected to provide valuable insights into its potential activity for the treatment of PD.